CN107648249A - Application of the desgalactotigonin in the medicine for preparing preventing and treating influenza infection - Google Patents
Application of the desgalactotigonin in the medicine for preparing preventing and treating influenza infection Download PDFInfo
- Publication number
- CN107648249A CN107648249A CN201710930552.6A CN201710930552A CN107648249A CN 107648249 A CN107648249 A CN 107648249A CN 201710930552 A CN201710930552 A CN 201710930552A CN 107648249 A CN107648249 A CN 107648249A
- Authority
- CN
- China
- Prior art keywords
- medicine
- desgalactotigonin
- influenza
- preventing
- influenza infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of the desgalactotigonin in the medicine for preparing preventing and treating influenza infection, described influenza virus refers to influenza A and Type B influenza virus；Influenza A therein refers to A3Type influenza virus；The medicine of described preventing and treating influenza infection also plays the active ingredient of compatibility synergy comprising acceptable auxiliary material with other.The desgalactotigonin of the present invention has good resisiting influenza virus infection effect, has no toxic side effect, therefore, available for the medicine for preparing preventing and treating influenza infection.
Description
Technical field
The invention belongs to medicinal natural product field, and in particular to desgalactotigonin is preparing preventing and treating influenza virus
Application in the medicine of infection.
Background technology
Influenza infection is a kind of Acute respiratory infectious disease, there is very strong infectiousness.Existing epidemiologic data shows
Show and be once very popular every 10 years or so.And influenza infection breaks out, distributed, prevalence then occurs frequently in all parts of the world,
Serious threat people especially the elderly and the health and life of for example chronic heart of other people at highest risk, tuberculosis or diabetic.
The traditional therapy of influenza infection is appropriate rest and symptomatic treatment, but it is to control to carry out treatment for cause of disease
The inevitable development for the treatment of means, the research to preventing and treating influenza infection medicine are always an important topic of study of pharmacy.
The structural formula of desgalactotigonin (degalactotigonin) is as follows：
The content of the invention
It is an object of the invention to provide desgalactotigonin in the medicine for preparing preventing and treating influenza infection
Using.
The purpose of the present invention is achieved through the following technical solutions：
Application of the desgalactotigonin in the medicine for preparing preventing and treating influenza infection；
Described influenza virus refers to influenza A and Type B influenza virus；
Described influenza A refers to A3Type influenza virus；
In vitro test confirms that desgalactotigonin is to A3Type and Type B influenza virus have obvious inhibitory action；Animal
Antiviral assay in vivo result shows：Desgalactotigonin is in Mice Body to A3Type and Type B influenza virus have preferable
Inhibitory action.
The medicine of described preventing and treating influenza infection also plays compatibility synergy comprising acceptable auxiliary material and other
Active ingredient；
The medicine of described preventing and treating influenza infection can be various formulations, such as tablet, granule, capsule, dripping pill, slow
Release agent, oral liquid, injection etc..
The present invention is had the following advantages relative to prior art and effect：
The desgalactotigonin of the present invention has good resisiting influenza virus infection effect, has no toxic side effect, because
This, available for the medicine for preparing preventing and treating influenza infection.
Embodiment
With reference to embodiment, the present invention is described in further detail, but the implementation of the present invention is not limited to this.
Embodiment 1
Desgalactotigonin infected by influenza infects the inhibitory action of cytopathogenic effect
In being inoculated with 100TCID in MDCK blake bottles508 after (median tissue culture infective dose) virus liquid doubling dilution are dense
Degree, 37 DEG C are incubated 2 hours, and HankShi liquid adds desgalactotigonin maximal non-toxic concentration liquid after rinsing 2 times
(6.50mg/ml) multiple proportions release it is dilute after 5 various concentrations, be shown in Table 1.
37 DEG C are continued culture 3 days, observe cytopathy daily, and make hemagglutinative titer experiment.It is right to set the virazole positive simultaneously
Compareed according to group, virus control and cell blank, per 4 bottles of sample, experimental result is shown in Table 1.
It can be seen that：Each medication group is to A3Type and Type B influenza virus have certain inhibitory action；Desgalactotigonin group
(1:4) Type B virus institute cytopathogenic effect can be completely inhibited, to A3Type virus can produce partial inhibition；Galactolipin is removed for accusing
Saponin (1:4) there is obvious inhibitory action to the virus more than 8 times of dilutions.
The desgalactotigonin of table 1 is to A3The experimental result of type and Type B influenza virus inhibitory action
Embodiment 2
Resisiting influenza virus is tested in desgalactotigonin body
Using A3Type influenza virus liquid infecting mouse is model, observation low dosage test medicine, middle dosage test medicine, height
Dose of test medicine, positive control medicine (virazole) are to Lung Index of mice infected by Influenza virus, the influence of lung lesion degree.
It the results are shown in Table 2, the results showed that：Basic, normal, high three dosage groups of test medicine can significantly inhibit lung lesion degree,
Lung Exponent, statistically with significant difference, is prompted test medicine to have inside preferably and resisted compared with model control group
A3The effect of type influenza virus.
The desgalactotigonin of table 2 is to A3The experimental result of type influenza virus inhibitory action
Embodiment 3
Acute toxicity test in mice
It is administered using single oral, the maximum dosage test medicine allowed in observational technique is to toxicity caused by mouse
Reaction.As a result show：After the administration of desgalactotigonin 13.33g/kgbw single orals, mouse activity is normal, outward appearance,
Behavior, secretion, excreta etc. have no abnormal changes.Continuous Observation 14 days, is showed no abnormal response, during experiment, animal body
Weight is normal to be increased, and the observation period terminates rear cut open inspection and do not find that histoorgan abnormal pathologic changes.Prompting：Test medicine is to allow most
Heavy dose of 13.33g/kgbw single orals administration, mouse have no toxic reaction.
Embodiment 4
The preparation of desgalactotigonin tablet
175g desgalactotigonins are uniformly mixed with 300g starch, add 13g starch slurries (14wt%) stirring system soft
Material, granulation, 22g superfine silica gel powders are added after drying, whole grain, tabletting, 1000 are made altogether, every weighs about as 0.5g.
Above-described embodiment is the preferable embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any Spirit Essences without departing from the present invention with made under principle change, modification, replacement, combine, simplification,
Equivalent substitute mode is should be, is included within protection scope of the present invention.
Claims (5)
1. application of the desgalactotigonin in the medicine for preparing preventing and treating influenza infection.
2. desgalactotigonin according to claim 1 answering in the medicine for preparing preventing and treating influenza infection
With, it is characterised in that：Described influenza virus refers to influenza A and Type B influenza virus.
3. desgalactotigonin according to claim 2 answering in the medicine for preparing preventing and treating influenza infection
With, it is characterised in that：Described influenza A refers to A3Type influenza virus.
4. desgalactotigonin according to claim 1 answering in the medicine for preparing preventing and treating influenza infection
With, it is characterised in that：The medicine of described preventing and treating influenza infection also plays compatibility collaboration comprising acceptable auxiliary material and other
The active ingredient of effect.
5. desgalactotigonin according to claim 1 answering in the medicine for preparing preventing and treating influenza infection
With, it is characterised in that：The medicine of described preventing and treating influenza infection is tablet, granule, capsule, dripping pill, sustained release agent, oral
Liquid or injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710930552.6A CN107648249B (en) | 2017-10-09 | 2017-10-09 | Application of the desgalactotigonin in the drug for preparing prevention influenza infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710930552.6A CN107648249B (en) | 2017-10-09 | 2017-10-09 | Application of the desgalactotigonin in the drug for preparing prevention influenza infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107648249A true CN107648249A (en) | 2018-02-02 |
| CN107648249B CN107648249B (en) | 2018-11-06 |
Family
ID=61116072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710930552.6A Expired - Fee Related CN107648249B (en) | 2017-10-09 | 2017-10-09 | Application of the desgalactotigonin in the drug for preparing prevention influenza infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107648249B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546881A (en) * | 2014-12-12 | 2015-04-29 | 贵州省生物研究所 | Application of degalactotigonin and derivative thereof in preparation of broad-spectrum antitumor medicine |
-
2017
- 2017-10-09 CN CN201710930552.6A patent/CN107648249B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104546881A (en) * | 2014-12-12 | 2015-04-29 | 贵州省生物研究所 | Application of degalactotigonin and derivative thereof in preparation of broad-spectrum antitumor medicine |
Non-Patent Citations (2)
| Title |
|---|
| FREW, T ET AL: "A MULTIWELL ASSAY FOR INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE AND THE IDENTIFICATION OF NATURAL PRODUCT INHIBITORS", 《ANTICANCER RESEARCH》 * |
| MING-SIAN WU ET AL.: "Mechanism of action of the suppression of influenza virus replication by Ko-Ken Tang through inhibition of the phosphatidylinositol 3-kinase/Akt signaling pathway and viral RNP nuclear export", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107648249B (en) | 2018-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230081837A1 (en) | Products of manufacture and methods for treating, ameliorating or preventing coronavirus infection | |
| CN106668832B (en) | Application of polypeptide in preparation of medicine for treating enterovirus infection | |
| CN102085311B (en) | Traditional Chinese medicinal composition for preventing or treating common cold and/or flu, method for preparing same and application thereof | |
| KR101437708B1 (en) | Antiviral composition and method of use | |
| CN104840467A (en) | Pentacyclic triterpene enterovirus EV71 inhibitors, and medicinal compositions and medicinal use thereof | |
| US20160151436A1 (en) | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | |
| CN103446051A (en) | Method for administrating preparations containing peramivir and/or derivatives thereof | |
| JP2022019937A (en) | Composition for preventing or treating chronic or acute virus infection and/or sepsis in humans or animals | |
| CA2465062C (en) | Preventive and/or therapeutic agent for viral infection | |
| Stefanou et al. | Pomegranate as an anti-viral agent and immune system stimulant | |
| JP2010083758A (en) | Antiviral agent | |
| CN107648249B (en) | Application of the desgalactotigonin in the drug for preparing prevention influenza infection | |
| CN106344549B (en) | Application of the Rhein in preparation prevention and/or treatment hand-foot-and-mouth disease drug | |
| CN106265684A (en) | The application of Lupenyl acetate | |
| CN101757016A (en) | Medicine composition for treating flu and preparation method thereof | |
| CN106336447B (en) | The application of celastrin | |
| CN106377537B (en) | Application of acetyl astragaloside | |
| CN104161902B (en) | A kind of new application of pharmaceutical composition and its preparation in Tamiflu is prepared | |
| CN106243102B (en) | The application of alkaloid compound | |
| CN106943390B (en) | Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament | |
| CN110179785B (en) | Application of widmanone in preparation of medicine for treating or preventing hand-foot-and-mouth disease | |
| CN113546067B (en) | Anthraquinone derivatives with antiviral effect | |
| US20210346459A1 (en) | Application of Dalargin for the prevention of VRIs and prevention of the development of complications during VRIs | |
| CN101247802A (en) | Methods and compositions for inhibiting, destroying, and/or inactivating viruses | |
| CN107595868B (en) | Application of the desgalactotigonin in preparation treatment bronchitis drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181106 Termination date: 20211009 |